World game at war: why some European nations have threatened a World Cup boycott 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Press release - No. 10 / 2018
Zealand Pharma will attend the Kempen Life Science Conference on April 18, 2018 in Amsterdam
Copenhagen, April 12, 2018 - Mats Blom, Executive Vice President and Chief Financial Officer (CFO) of Zealand Pharma, will attend the Kempen Life Science Conference in Amsterdam on April 18, 2018.
For further information, please contact:
Britt Meelby Jensen, President and Chief Executive Officer
Tel: +45 51 67 61 28, e-mail: [email protected]
Mats Blom, Senior Vice President, Chief Financial Officer
Tel: +45 31 53 79 73, e-mail: [email protected]
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi and Boehringer Ingelheim, and a pipeline of internal product candidates focusing on specialty gastrointestinal and metabolic diseases.
Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.
Attachment
